Development of a dual nanocarrier system as a potential stratagem against amyloid-induced toxicity

Bibliography

• Rafii MS, Aisen PS. Recent developments in Alzheimer’s disease therapeutics. BMC Med 2009;7:7-10
   PubMed Web of Science ®Google Scholar
• Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer’s disease: phenomenology and treatment. J Clin Psychiatry 1987;48(5):9-15
   PubMed Web of Science ®Google Scholar
• Wang Y-J, Zhou H-D, Zhou X-F. Clearance of amyloid-beta in Alzheimer’s disease: progress, problems and perspectives. Drug Discov Today 2006;11:931-8
   PubMed Web of Science ®Google Scholar
• Tay WM, Huang D, Rosenberry TL, et al. The Alzheimer’s amyloid-beta (1-42) peptide forms off-pathway oligomers and fibrils that are distinguished structurally by intermolecular organization. J Mol Biol 2013;425(14):2494-508
   PubMed Web of Science ®Google Scholar
• Sabbagh MN. Drug development for Alzheimer’s disease: where are we now and where are we headed? Am J Geriatr Pharmacother 2009;7(3):167-85
   PubMed Web of Science ®Google Scholar
• Kumaraswamy P, Sethuramanan S, Krishnan UM. Hierarchical self-assembly of Tjernberg peptide at nanoscale. Soft Matter 2013;9:2684-94
   Web of Science ®Google Scholar
• Kumaraswamy P, Sethuraman S, Krishnan UM. Mechanistic insights of curcumin interactions with the core-recognition motif of beta-amyloid peptide. J Agric Food Chem 2013;61(13):3278-85
   PubMed Web of Science ®Google Scholar
• Li F, Gong Q, Dong H, et al. Resveratrol, a neuroprotective supplement for Alzheimer’s disease. Curr Pharm Des 2012;18(1):27-33
   PubMed Web of Science ®Google Scholar
• Valles SL, Dolz-Gaiton P, Gambini J, et al. Estradiol or genistein prevent Alzheimer’s disease-associated inflammation correlating with an increase PPAR gamma expression in cultured astrocytes. Brain Res 2010;1312:138-44
   PubMed Web of Science ®Google Scholar
• George RC, Lew J, Graves DJ. Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating alzheimer’s disease pathogenesis. J Alzheimers Dis 2013;36(1):21-40
   PubMed Web of Science ®Google Scholar
• Vauthier C, Labarre D, Ponchel G. Design aspects of poly(alkylcyanoacrylate) nanoparticles for drug delivery. J Drug Target 2007;15:641-63
   PubMed Web of Science ®Google Scholar
• Mishra V, Mahor S, Rawat A, et al. Targeted brain delivery of AZT via transferring anchored pegylated albumin nanoparticles. J Drug Target 2006;14:45-53
   PubMed Web of Science ®Google Scholar
• Mathew A, Fukuda T, Nagaoka Y, et al. Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer’s disease. PLoS One 2012;7(3):e32616
   PubMed Web of Science ®Google Scholar
• Spuch C, Navarro C. Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer’s Disease and Parkinson’s disease). J Drug Deliv 2011;2011:469679
   PubMedGoogle Scholar
• Yusuf M, Khan M, Khan RA, et al. Preparation, characterization, in vivo and biochemical evaluation of brain targeted piperine solid lipid nanoparticles in an experimentally induced Alzheimer’s disease model. J Drug Target 2013;21(3):300-11
   PubMed Web of Science ®Google Scholar
• Sharma A, Sharma US. Liposomes in drug delivery: progress and Limitations. Int J Pharm 1997;154(2):123-40
   Web of Science ®Google Scholar
• Huang FY, Chen WJ, Lee WY, et al. In vitro and in vivo evaluation of lactoferrin-conjugated liposomes as a novel carrier to improve the brain delivery. Int J Mol Sci 2013;14(2):2862-74
   PubMed Web of Science ®Google Scholar
• Phachonpai W, Wattanathorn J, Muchimapura S, et al. Neuroprotective effect of quercetin encapsulated liposomes: a novel therapeutic strategy against Alzheimer’s disease. Am J Appl Sci 2010;7(4):480-5
   Google Scholar
• Mutlu NB, Degim Z, Yilmaz S, et al. New perspective for the treatment of Alzheimer’s disease: liposomal rivastigmine formulations. Drug Dev Ind Pharm 2011;37(7):775-89
   PubMed Web of Science ®Google Scholar
• Mourtas S, Canovi M, Zona C, et al. Curcumin-decorated nanoliposomes with very high affinity for amyloid-beta1-42 peptide. Biomaterials 2010;31(25):6519-29
   PubMedGoogle Scholar
• Zako K, Sakaguchi M, Komizu Y, et al. Experimental therapeutic effects of hybrid liposomes on the Alzheimer’s disease in vitro. Yakugaku Zasshi 2011;131(5):775-82
   PubMed Web of Science ®Google Scholar
• Eckert GP, Chang S, Eckmann J, et al. Liposome-incorporated DHA increases neuronal survival by enhancing non-amyloidogenic APP processing. Biochim Biophys Acta 2011;1808(1):236-43
   PubMed Web of Science ®Google Scholar
• Gobbi M, Re F, Canovi M, et al. Lipid-based nanoparticles with high binding affinity for amyloid - beta1-42 peptide. Biomaterials 2010;31(25):6519-29
   PubMed Web of Science ®Google Scholar
• Canovi M, Markoutsa E, Lazar AN, et al. The binding of anti-Abeta1-42 MAb-decorated nanoliposomes to Abeta1-42 peptides in vitro and to amyloid deposits in post mortem tissue. Biomaterials 2011;32(23):5489-97
   PubMed Web of Science ®Google Scholar
• Arumugam K, Subramanian GS, Mallayasamy SR, et al. A study of rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharm 2008;58(3):287-97
   PubMed Web of Science ®Google Scholar
• Leung MH, Kee TW. Effective stabilization of curcumin by association to plasma proteins: human serum albumin and fibrinogen. Langmuir 2009;25(10):5773-7
   PubMed Web of Science ®Google Scholar
• Ramana LN, Sethuraman S, Udaykumar R, et al. Development of a liposomal nanodelivery system for nevirapine. J Biomed Sci 2010;17:57-65
   PubMed Web of Science ®Google Scholar
• Hansen TW, DeLaRiva AT, Challa SR, et al. Sintering of catalytic nanoparticles: particle migration or Ostwald ripening? Acc Chem Res 2013;46(8):1720-30
   PubMed Web of Science ®Google Scholar
• Ghosh S, Bull HB. Adsorbed films of bovine serum albumin: Tensions at air-water surfaces and paraffin-water interfaces. Biochem Biophys Acta 1963;66:150-7
   PubMed Web of Science ®Google Scholar
• Kagan BL, Thundimadathil J. Amyloid peptide pores and the beta sheet conformation. Adv Exp Med Biol 2010;677:150-67
   PubMed Web of Science ®Google Scholar
• Yip CM, McLaurin J. Amyloid-beta peptide assembly: a critical step in fibrillogenesis and membrane disruption. Biophys J 2001;80(3):1359-71
   PubMed Web of Science ®Google Scholar
• Moss Ma, Nichols MR, Reed DK, et al. The peptide KLVFF-K6 promotes beta-amyloid (1-40) protofibril growth by association but doesnot alter protofibril effects on cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). Mol Pharmacol 2003;64(5):1160-8
   PubMed Web of Science ®Google Scholar
• Lai F, Fadda AM, Sinico C. Liposomes for brain delivery. Expert Opin Drug Deliv 2013;10(7):1003-22
   PubMed Web of Science ®Google Scholar
• Shehzad A, Khan S, Shehzad O, et al. Curcumin therapeutic promises and bioavailability in colorectal cancer. Drugs Today (Barc) 2010;46(7):523-32
   PubMed Web of Science ®Google Scholar
• Purkayastha S, Berliner A, Fernando SS, et al. Curcumin blocks brain tumor formation. Brain Res 2009;1266:130-8
   PubMed Web of Science ®Google Scholar